{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:18:37Z","timestamp":1789676317500,"version":"4.0.1"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.steroids.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T20:02:34Z","timestamp":1483041754000},"page":"76-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Synthetic approaches towards the multi target drug spironolactone and its potent analogues\/derivatives"],"prefix":"10.1016","volume":"118","author":[{"given":"Fayaz Ali","family":"Larik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"El-Seedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Mehfooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervaiz Ali","family":"Channar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2016.12.010_h0005","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/ja01574a058","article-title":"Steroidal lactones","volume":"79","author":"Kagawa","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2016.12.010_h0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1021\/jo01090a019","article-title":"Steroidal aldosterone blockers. II1","volume":"24","author":"Cella","year":"1959","journal-title":"J. Org. Chem"},{"key":"10.1016\/j.steroids.2016.12.010_h0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/jo01088a004","article-title":"Steroidal aldosterone blockers","volume":"24","author":"Cella","year":"1959","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_h0020","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/ja01574a058","article-title":"Steroidal lactones","volume":"79","author":"Cella","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2016.12.010_h0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/jo01071a027","article-title":"Steroidal aldosterone blockers. III 1, 2","volume":"25","author":"Brown","year":"1960","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_h0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.steroids.2016.12.010_h0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.steroids.2016.12.010_h0040","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.steroids.2016.12.010_h0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9149(90)91281-A","article-title":"Spironolactone in the management of congestive heart failure","volume":"65","author":"Muller","year":"1990","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.steroids.2016.12.010_h0050","first-page":"52","article-title":"Aldosterone antagonists in hypertension and heart failure","volume":"61","author":"Mantero","year":"2000","journal-title":"Ann. Endocrinol."},{"issue":"22 Supplement","key":"10.1016\/j.steroids.2016.12.010_h0055","first-page":"A16910","article-title":"Can spironolactone mitigate myocardial fibrosis and alter sudden death risk and heart failure symptoms in patients with hypertrophic cardiomyopathy?: A prospective, randomized trial","volume":"128","author":"Maron","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0060","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.steroids.2016.12.010_h0065","unstructured":"K. Kota, K. Kota, K. Meher, D. Modi, Spironolactone; the ultimate blocker of RAAS cascade in hypertensive patients with special reference to its cardiovascular benefits: Revisiting the forgotten ways, 2012."},{"issue":"6","key":"10.1016\/j.steroids.2016.12.010_h0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jash.2010.09.006","article-title":"Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy","volume":"4","author":"Heshka","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.steroids.2016.12.010_h0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.1E618","article-title":"Clinical experience with spironolactone in pediatrics","volume":"39","author":"Buck","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.steroids.2016.12.010_h0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11894-003-0026-6","article-title":"Pathophysiology and management of pediatric ascites","volume":"5","author":"Sabri","year":"2003","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14227\/DT210114P19","article-title":"Development, physical-chemical stability, and release studies of four alcohol-free spironolactone suspensions for use in pediatrics","volume":"21","author":"Bernal","year":"2014","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.steroids.2016.12.010_h0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.1961.03040220017003","article-title":"Use of spironolactone in renal edema: effectiveness and association with hyperkalemia","volume":"176","author":"Manning","year":"1961","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.steroids.2016.12.010_h0100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol. Res."},{"issue":"3","key":"10.1016\/j.steroids.2016.12.010_h0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-90-3-338","article-title":"Spironolactone-induced hyperchloremic acidosis in cirrhosis","volume":"90","author":"Gabow","year":"1979","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.steroids.2016.12.010_h0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety","volume":"39","author":"Santos","year":"2003","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.steroids.2016.12.010_h0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000199198","article-title":"Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites","volume":"31","author":"Bernardi","year":"1985","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.steroids.2016.12.010_h0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.steroids.2016.12.010_h0130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.steroids.2016.12.010_h0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40620-014-0059-y","article-title":"Single-side renal sympathetic denervation to treat malignant refractory hypertension in a solitary kidney patient","volume":"27","author":"Ribichini","year":"2014","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.steroids.2016.12.010_h0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.steroids.2016.12.010_h0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpt1977212234","article-title":"Metolazone and spironolactone in cirrhosis and the nephrotic syndrome","volume":"21","author":"Lang","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.steroids.2016.12.010_h0150","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.steroids.2016.12.010_h0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J. Hypertens."},{"issue":"10","key":"10.1016\/j.steroids.2016.12.010_h0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/CIRCULATIONAHA.105.570192","article-title":"Diuretics for hypertension","volume":"112","author":"Krakoff","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.steroids.2016.12.010_h0165","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J. Hum. Hypertens."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.steroids.2016.12.010_h0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0022-3476(79)80442-4","article-title":"Bronchopulmonary dysplasia: clinical presentation","volume":"95","author":"Bancalari","year":"1979","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clp.2011.12.007","article-title":"Neonatal diuretic therapy: furosemide, thiazides, and spironolactone","volume":"39","author":"Segar","year":"2012","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.steroids.2016.12.010_h0185","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/598606","article-title":"Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia","author":"Tropea","year":"2012","journal-title":"Int. J. Pediatr."},{"issue":"3","key":"10.1016\/j.steroids.2016.12.010_h0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/CPM.0b013e318218a071","article-title":"\u201cNew\u201d bronchopulmonary dysplasia: a clinical review","volume":"18","author":"Bhandari","year":"2011","journal-title":"Clin. Pulm. Med."},{"key":"10.1016\/j.steroids.2016.12.010_h0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/jcem-45-2-255","article-title":"Gynecomastia and semen abnormalities induced by spironolactone in normal men","volume":"45","author":"Caminos-Torres","year":"1977","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2016.12.010_h0200","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1095\/biolreprod27.4.771","article-title":"Effects of spironolactone (aldosterone antagonist) on electrolyte and water content of the cauda epididymidis and fertility of male rats","volume":"27","author":"Wong","year":"1982","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.steroids.2016.12.010_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF01497314","article-title":"Beeinflussung mikrosomaler Enzyme der Rattenleber durch Spironolacton, Etacryns\u00e4ure und Furosemid","volume":"49","author":"Leber","year":"1971","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.steroids.2016.12.010_h0210","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0039-128X(69)80007-3","article-title":"Anti-androgenic activity of spironolactone","volume":"14","author":"Steelman","year":"1969","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.steroids.2016.12.010_h0215","first-page":"1149","article-title":"Breast imaging in the transgender patient","volume":"202","author":"Phillips","year":"2014","journal-title":"Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12471-013-0482-z","article-title":"A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice","volume":"22","author":"Nicolai","year":"2014","journal-title":"Neth. Heart. J."},{"key":"10.1016\/j.steroids.2016.12.010_b0080","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1963.73700230005018","article-title":"Gynecomastia during therapy with spironolactone","volume":"184","author":"Mann","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2016.12.010_h0230","series-title":"Analytical Profiles of Drug Substances and Excipients","first-page":"23","author":"Brittain","year":"1994"},{"key":"10.1016\/j.steroids.2016.12.010_h0235","unstructured":"Kirth-Othmer Encyclopedia of Chemical Technology, fourth ed."},{"key":"10.1016\/j.steroids.2016.12.010_h0240","unstructured":"G. Anner, H. Wehrli (Ciba-Geigy, A.-G.), German Offen 2, 625, 723 (cl.C07J21\/ 00), Dec. 1976; Swiss Appl. 75\/7, 696(13), Jun. 1975, 37."},{"key":"10.1016\/j.steroids.2016.12.010_b0090","first-page":"132","author":"Brittain","year":"2002","journal-title":"Anal. Prof. Drug Subst. Excip."},{"key":"10.1016\/j.steroids.2016.12.010_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1075-6280(02)29009-6","article-title":"Spironolactone","volume":"29","author":"Al-Hadiya","year":"2002","journal-title":"Anal. Prof. Drug Subst. Excip."},{"key":"10.1016\/j.steroids.2016.12.010_b0100","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1021\/jo00282a041","article-title":"A novel synthesis of spironolactone. An application of the hydroformylationreaction","volume":"54","author":"Wuts","year":"1989","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_b0105","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/ja00376a046","article-title":"Stereoselective induction of biomimetic polyene cyclizations by remote chiral centers. Effect of a pro-C-7 substituent in a substrate leading to steroidal products","volume":"104","author":"Johnson","year":"1982","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2016.12.010_b0110","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1021\/ja00376a047","article-title":"Total synthesis of dl-spironolactone and dl-19-norspironolactone by biomimetic polyene cyclization methodology","volume":"104","author":"Johnson","year":"1982","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2016.12.010_b0115","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1021\/ja00217a040","article-title":"A novel strategy for the stereoselective total synthesis of C-17 spiro steroids. Total synthesis of 19-norcanrenone-a formal total synthesis of 19-norspironolactone","volume":"110","author":"Nemoto","year":"1988","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2016.12.010_b0120","series-title":"Ring Enlargement in Organic Chemistry","author":"Hesse","year":"1991"},{"key":"10.1016\/j.steroids.2016.12.010_b0125","unstructured":"J.C. Somberg, V.V. Ranade, John C. Somberg, Vassant V. Ranade, Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action, U.S. Patent Application 214 (2008) 352."},{"key":"10.1016\/j.steroids.2016.12.010_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.steroids.2015.07.008","article-title":"A new approach towards the synthesis of drospirenone and steroidal spirolactones","volume":"102","author":"Santhamma","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_h0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2016.12.010_h0295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3565(25)31630-7","article-title":"SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone","volume":"209","author":"Cutler","year":"1979","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.steroids.2016.12.010_h0300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/jcem-47-1-171","article-title":"25152: a potent mineralocorticoid antagonist with reduced affinity for the 5\u03b1-dihydrotestosterone receptor of human and rat prostate","volume":"47","author":"Cutler","year":"1978","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2016.12.010_h0305","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0035-1561848","article-title":"Facile access to 3, 7-dialkyltetrahydro-1H, 5H-[1, 2, 4] triazolo [1, 2-a][1, 2, 4] triazole-1, 5-dithiones","volume":"27","author":"Saeed","year":"2016","journal-title":"Synlett"},{"key":"10.1016\/j.steroids.2016.12.010_h0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cpt1978244465","article-title":"Gynecomastia induced in normal males by spironolactone","volume":"24","author":"Huffman","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.steroids.2016.12.010_h0315","first-page":"49","article-title":"Pharmacological studies on new steroidal aldosterone antagonists: I. Antialdosterone activity in rats and in healthy man","volume":"316","author":"Casals-Stenzel","year":"1981","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.steroids.2016.12.010_h0320","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0022-4731(83)90010-9","article-title":"Synthesis and activities of anti-aldosterones","volume":"19","author":"Laurent","year":"1983","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2016.12.010_b0145","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1039\/J39680002346","article-title":"Synthetic steroids. Part VII. The preparation of 3\u03b2, 14\u03b2-dihydroxy-androst-5-en-17-one","author":"Sykes","year":"1968","journal-title":"J. Chem. Soc. C Organic"},{"key":"10.1016\/j.steroids.2016.12.010_b0150","doi-asserted-by":"crossref","unstructured":"J. R. Hanson, A.W. Johnson, M.A.C. Kaplan, J.C.S. Perkitt I (1978) 263.","DOI":"10.1039\/P19780000263"},{"key":"10.1016\/j.steroids.2016.12.010_b0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1039\/J39680000416","article-title":"Synthetic steroids. Part III. The preparation of 3\u03b2, 15\u03b2, 17\u03b2-trihydroxyandrost-5-ene and the attempted preparation of 3\u03b2, 15\u03b1, 17\u03b2-trihydroxyandrost-5-ene","author":"Kelly","year":"1968","journal-title":"J. Chem. Soc. C Organic"},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_h0340","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone. a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.steroids.2016.12.010_h0345","first-page":"459","article-title":"Progestogens with antimineralocorticoid activity","volume":"35","author":"Losert","year":"1984","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.steroids.2016.12.010_h0350","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/1570193X13666160618074751","article-title":"Synthetic approaches to the multifunctional drug ebselen and analogs: past and present","volume":"13","author":"Saeed","year":"2016","journal-title":"Mini-Rev. Org. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_h0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/acta.0.109S131","article-title":"Interaction of spirorenone and related compounds with renal mineralocorticoid receptors and with androgen receptors in human prostate cytosol","volume":"110","author":"Wambach","year":"1985","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.steroids.2016.12.010_h0360","first-page":"296","article-title":"Problems of dose finding: sexual hormones (author\u2019s transl)","volume":"27","author":"Neumann","year":"1977","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.steroids.2016.12.010_h0365","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/jm50001a002","article-title":"Aldosterone antagonists. 1. Synthesis and activities of 6\u03b2, 7\u03b2: 15\u03b2, 16\u03b2-dimethylene steroidal spirolactones","volume":"28","author":"Nickisch","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_h0370","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.tetasy.2016.09.007","article-title":"Stereoselective synthetic approaches towards (S)-duloxetine: 2000 to date","volume":"27","author":"Larik","year":"2016","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1016\/j.steroids.2016.12.010_b0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00543796","article-title":"Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses","volume":"25","author":"Krause","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.steroids.2016.12.010_b0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0039-128X(82)90114-3","article-title":"Isolation and identification of spirorenone metabolites from the monkey (Macaca fascicularis)","volume":"40","author":"Krause","year":"1982","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_b0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0039-128X(82)90031-9","article-title":"Synthesis and pharmacological evaluation of 8\u03b1-estradiol derivatives","volume":"40","author":"Gonzalez","year":"1982","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_b0185","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/jm50001a002","article-title":"Aldosterone antagonists. 1. Synthesis and activities of 6\u03b2, 7\u03b2: 15\u03b2, 16\u03b2-dimethylene steroidal spirolactones","volume":"28","author":"Nickisch","year":"1985","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_b0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0039-128X(82)90031-9","article-title":"Synthesis and pharmacological evaluation of 8\u03b1-estradiol derivatives","volume":"40","author":"Gonzlles","year":"1982","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_b0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00498838","article-title":"Pharmacokinetics of spironolactone in man","volume":"296","author":"Abshagen","year":"1976","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.steroids.2016.12.010_b0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0039-128X(72)90117-1","article-title":"Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone\u00ae)","volume":"20","author":"Karim","year":"1972","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_b0205","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"De Gasparo","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.steroids.2016.12.010_b0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.steroids.2016.12.010_b0215","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0731-7085(96)01767-0","article-title":"Simultaneous determination of spironolactone and its metabolites in human plasma","volume":"14","author":"Jankowski","year":"1996","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.steroids.2016.12.010_b0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0090-9556(25)08203-0","article-title":"Identification of spironolactone metabolites in plasma and target organs of guinea pigs","volume":"21","author":"Los","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.steroids.2016.12.010_b0225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1081\/DDC-52182","article-title":"Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound","volume":"31","author":"Langguth","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.steroids.2016.12.010_b0230","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.steroids.2007.03.011","article-title":"Stereoselective synthesis of the two major metabolites of spironolactone, 3\u03b1-and 3\u03b2-hydroxy-7\u03b1-methylthio-17\u03b1-pregn-4-ene-21, 17 carbolactone","volume":"72","author":"Li","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_b0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.steroids.2012.09.005","article-title":"A safe and practical method for the preparation of 7\u03b1-thioether and thioester derivatives of spironolactone","volume":"78","author":"Agusti","year":"2013","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.12.010_b0240","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2174\/187152009788680000","article-title":"Advances in development of inhibitors of 17\u03b2-hydroxysteroid dehydrogenases","volume":"9","author":"Poirier","year":"2009","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_b0245","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/0929867033368222","article-title":"Inhibitors of 17b-hydroxysteroid dehydrogenases","volume":"10","author":"Poirier","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_b0250","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0968-0896(98)00260-0","article-title":"Spironolactone-related inhibitors of type II 17b-hydroxysteroiddehydrogenase: chemical synthesis, receptor binding affinities and proliferative\/antiproliferative activities","volume":"7","author":"Tremblay","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2016.12.010_b0255","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1016\/j.bmcl.2014.05.038","article-title":"Synthesis of two new hydroxylated derivatives of spironolactone by microbial transformation","volume":"24","author":"Mei","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2016.12.010_b0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2016.12.010_h0470","first-page":"709","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"J. Med."},{"issue":"8","key":"10.1016\/j.steroids.2016.12.010_h0475","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J. Card. Fail."},{"issue":"12","key":"10.1016\/j.steroids.2016.12.010_h0480","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2169\/internalmedicine.55.6303","article-title":"Effectiveness of high-dose spironolactone therapy in a patient with recurrent protein-losing enteropathy after the Fontan procedure","volume":"55","author":"Okano","year":"2016","journal-title":"Intern. Med."},{"key":"10.1016\/j.steroids.2016.12.010_h0485","first-page":"A7380","article-title":"Effects of spironolactone in pulmonary arterial hypertension: results of spiro study. In D54","author":"Tamez","year":"2016","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.steroids.2016.12.010_h0490","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejim.2012.11.007","article-title":"Evolving strategies for the use of spironolactone in cardiovascular disease","volume":"24","author":"Jolobe","year":"2013","journal-title":"Eur. J. Intern. Med."},{"issue":"11","key":"10.1016\/j.steroids.2016.12.010_h0495","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1210\/en.2010-0465","article-title":"Minireview: aldosterone and mineralocorticoid receptors: past, present, and future","volume":"151","author":"Funder","year":"2010","journal-title":"J. Endocrinol."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X16301982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X16301982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:19:15Z","timestamp":1749856755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X16301982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":99,"alternative-id":["S0039128X16301982"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2016.12.010","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic approaches towards the multi target drug spironolactone and its potent analogues\/derivatives","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}